It looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in the coming months after backing from an FDA expert commit
The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition.
The FDA has finally approved Teva’s potential blockbuster migraine drug Ajovy after months of delays due to concerns about the manufacturing plant operated by the company’s partner, Celltri
